Bufalin Induces Programmed Necroptosis in Triple-Negative Breast Cancer Drug-Resistant Cell Lines through RIP1/ROS-Mediated Pathway
Abstract
Objective To explore the effect and mechanism of action of bufalin in triple-negative breast cancer (TNBC) drug-resistant cell lines. Methods The normal human mammary epithelial cell line, TNBC cell line, TNBC adriamycin-resistant cell line, and TNBC docetaxel-resistant cell line were treated with different doses of bufalin (0-1,000 nmol/L) at different time points (0-72 h). Propidium iodide staining, AV-FITC/PI double staining, Hoechst 33342/PI double staining and transmission electron microscopy (TEM) were used to evaluate the death patterns of the cell lines. Results Bufalin killed the TNBC cell line and its drug-resistant cell lines in a dose/time-dependent manner (all P Conclusions Bufalin could induce necroptosis through RIP1/ROS-mediated pathway to kill the drug-resistant TNBC cell lines. This finding provides critical experimental data and theoretical basis for the clinical application of bufalin to overcome the difficulties in the treatment of TNBC.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Bufalin induced apoptosis, necroptosis, ferroptosis, autophagy, and senescence through AMPK, RIP1/ROS, DECR1, p62, and p53 pathways.
“Bufalin induced apoptosis, necroptosis, ferroptosis, autophagy, and senescence through AMPK, RIP1/ROS, DECR1, p62, and p53 pathways5,44–48.”
From Harnessing artificial intelligence to identify Bufalin as a molecular glue degrader of estrogen receptor alpha (2025) · cites this paper as [47]
Cites
Rastogi, R. P., Singh, S. P., Häder, D.-P., & Sinha, R. P. (2010) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2010.06.006 · Cited by 479 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Wu, S., Wu, X., Wang, Q., Chen, Z., Li, L., Chen, H., & Qi, H. (2024) · Phytomedicine · doi:10.1016/j.phymed.2024.156130 · Cited by 27 · see citing works
Jiang, S., Liu, K., Jiang, T., Li, H., Wei, X., Wan, X., Zhong, C., Gong, R., Chen, Z., Zou, C., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-62288-7 · Cited by 23 · see citing works
Ye, Q., Zhou, X., Ren, H., Han, F., Lin, R., & Li, J. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1274336 · Cited by 15 · see citing works
- Authors
- Liu, X.-D., Song, C.-Y., Kong, C.-C., & Tian, X.
- Affiliations
- First Hospital of China Medical University (CN)
- Corresponding author
- Tian, Xin
- ORCID
- Tian, Xin
- Venue
- Chinese Journal of Integrative Medicine
- Published
- 2021-11-26
- Volume
- 28
- Issue
- 10
- Pages
- 900-908
- ISSN
- 1672-0415 (ISSN-L)
- 1993-0402
- OpenAlex
- W3215038008
- Cited by
- 21
- References
- 1
- Citations by year
- 2026: 2 · 2025: 6 · 2024: 6 · 2023: 5 · 2022: 2
- FWCI
- 1.02
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Chinese Journal of Integrative Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cell death mechanisms and regulation
- Health Sciences › Medicine › Complementary and alternative medicine › Natural Compounds in Disease Treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Natural product bioactivities and synthesis
- Keywords
- bufalin, triple-negative breast cancer, drug resistance, necroptosis, RIPK1, reactive oxygen species, doxorubicin resistance, docetaxel resistance, apoptosis, Nec-1, N-acetylcysteine, tumor necrosis factor receptor 1, caspase-3
- MeSH terms
- Docetaxel, Necroptosis, Antioxidants, Bufanolides, Cell Line, Cysteine, Doxorubicin, Humans, Propidium, Tumor Necrosis Factor-alpha, Fluorescein-5-isothiocyanate, Apoptosis, Reactive Oxygen Species, Receptors, Tumor Necrosis Factor, Cell Line, Tumor, Caspase 3, Triple Negative Breast Neoplasms
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
